You searched for "VEGF"

185 results found

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

RaScaL Study

The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...

Data update for leading causes of CVI in England and Wales

In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...

Oxford Handbook of Ophthalmology Third Edition

The Oxford Handbook of Ophthalmology came out in 2006 and is now in its third edition. It is a valuable concise resource with over 1000 pages to cover initial assessment, diagnosis and management of a comprehensive range of ophthalmic problems....

Ophthalmology (third edition)

If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...

Antibiotic prophylaxis after intravitreal injections

The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office...

New mouse model of diabetes mellitus

Diabetic retinopathy (DR) is a serious complication of diabetes. It is driven by the loss of pericytes, cells which control vascular function, due to excess formation of sugar alcohols by the enzyme aldose reductase (AR). AR has been shown to...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

Zero Residual™ reduces the cost of intravitreal injections

At a time when patient numbers are increasing and budgets are stretched, reducing costs in expensive wet-AMD treatments can be achieved with the Zero Residual™ Concept.

Cataract surgery in patients being treated for neovascular AMD

This retrospective matched case control study evaluated outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age related macular degeneration (nAMD). They compared 124 patients that had cataract surgery with 372...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...

Outcomes of ‘treat and extend’ for neovascular AMD

The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...